AR086589A1 - Compuestos imidazopiridina - Google Patents
Compuestos imidazopiridinaInfo
- Publication number
- AR086589A1 AR086589A1 ARP120101881A ARP120101881A AR086589A1 AR 086589 A1 AR086589 A1 AR 086589A1 AR P120101881 A ARP120101881 A AR P120101881A AR P120101881 A ARP120101881 A AR P120101881A AR 086589 A1 AR086589 A1 AR 086589A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- group
- co2h
- co2r0
- phenylene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
Se proporciona un fármaco para tratar o prevenir enfermedades cardiovasculares, en base a acción que aumenta la producción de cGMP debido a acción activadora de guanilato ciclasa soluble. Se ha descubierto que compuestos de imidazopiridina que tienen un grupo carbamoilo en la posición 3 y un sustituyente unido en la posición 8 por medio de un átomo de oxígeno en un esqueleto de imidazo[1,2-a]piridina exhiben una acción que aumenta la producción de cGMP mediante una acción activadora de guanilato ciclasa soluble potente, y son útiles como un fármaco para tratar o prevenir diversas enfermedades cardiovasculares relacionadas con la guanilato ciclasa soluble.Reivindicación 1: Un compuesto de fórmula (1) o una sal del mismo, [los símbolos en la fórmula tienen los siguientes significados: A1: R0, -R00-(arilo), halógeno-alquilo inferior, cicloalquilo opcionalmente sustituido, heterocicloalquilo opcionalmente sustituido, arilo opcionalmente sustituido o heteroarilo opcionalmente sustituido; R0: iguales o diferentes entre sí y cada uno representa alquilo inferior; R00: iguales o diferentes entre sí y cada uno representa alquileno inferior; R1: H, R0, halógeno, -CN, -CO2H, -CO2R0 o -R00-OH; R2: H, R0, cicloalquilo C3-6 o halógeno-alquilo inferior; R3: H, R0, -R00-CO2H o -R00-CO2R0; R4: -Y-A2 o A3, o R3 y R4 junto con el átomo de N del cual ambos están unidos, pueden formar un heterociclo saturado que contiene nitrógeno opcionalmente sustituido con por lo menos un grupo seleccionado entre el grupo formado por en -OH, -R00-OH, -CO2H, -CO2R0, y fenilo; Y: alquileno C1-10 opcionalmente sustituido con por lo menos un grupo seleccionado del Grupo G2, alquenileno C2-10 opcionalmente sustituido con por lo menos un grupo seleccionado del Grupo G2 o -SO2-(alquileno inferior opcionalmente sustituido con por lo menos un grupo seleccionado del Grujo G2)-; Grupo G2: -CO2H, -CO2R0, -OH, -OR0, -O(CO)R0, -OSi(R0)3, -NH2, -NHR0, -N(R0)2, -NH-CO-R0, -SR0, -CO-NH-SO2-R0, arilo opcionalmente sustituido y heteroarilo opcionalmente sustituido; A2: H, -OH, -O-CO-R0, -O-(arilo), -CO-R0, -CO-R00-OH, -CO2-R0-(arilo), -CO-NH2, -CO-NHR0, -CO-N(R0)2, cicloalquilo opcionalmente sustituido, heterocicloalquilo opcionalmente sustituido, arilo opcionalmente sustituido o heteroarilo opcionalmente sustituido; A3: H, cicloalquilo opcionalmente sustituido con por lo menos un grupo seleccionado del Grupo G1, heterocicloalquilo opcionalmente sustituido con por o menos un grupo seleccionado del Grupo G1, arilo opcionalmente sustituido con por lo menos un grupo seleccionado del Grupo G1 o heteroarilo opcionalmente sustituido con por lo menos un grupo seleccionado del Grupo G1; Grupo G1: R0, halógeno-alquilo inferior, -R00-OH, halógeno, oxo, -NO2, -OH, -OR0, -O-R00-N(R0)2, -NH2, -CO-R0, -CO-R00-OH, -CO2H, -CO2R0, -CO-NH2, -CO-NHR0, -CO-N(R0)2, -CO2-R00-(fenilo), -SO2-R0, -SO2-NH2, -SO2-NHR0, -SO2-N(R0)2, -SO2-R00-CO2H, -SO2-R00-CO2R0, -SO2-(fenilo), -SO2-R00-(fenilo), -R00-CO2H, -R00-CO2R0, -R00-CO-NH2, -R00-CO-NHR0, -R00-CO2-N(R0)2, -R0-NH2, -R00-NHR0, -R00-N(R0)2, -R00-(fenilo), -R00-(fenileno)-R0, -R00-(cicloalquilo), -R00-(heterocicloalquilo), -R00-(heteroarilo que contiene nitrógeno monocíclico), cicloalquilo, fenilo, -(fenileno)-R0, -(fenileno)-CO2H, -(fenileno)-CO2R0, (piridindiil)-CO2H, -(piridindiil)-CO2R0, -(piperidindiil)-R0, -(fenileno)-R00-CO2H, -R00-(fenileno)-CO2H, -R00-(fenileno)-CO2R0, heteroarilo que contiene nitrógeno monocíclico y heterocicloalquilo; y R5: Iguales o diferentes entre sí y cada uno representa H o R0; siempre que el compuesto de fórmula (1) no sea 8-(benciloxi)-2-metilimidazo[1,2-3]piridin-3-carboxamida ni 8-(benciloxi)-2-metilimidazo[1,2-a]piridin-3-il](piperazin-1-il)metanona].
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011119826 | 2011-05-30 | ||
JP2011287682 | 2011-12-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR086589A1 true AR086589A1 (es) | 2014-01-08 |
Family
ID=47259254
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120101881A AR086589A1 (es) | 2011-05-30 | 2012-05-29 | Compuestos imidazopiridina |
Country Status (16)
Country | Link |
---|---|
US (1) | US9447090B2 (es) |
EP (1) | EP2716642B1 (es) |
JP (1) | JP5975025B2 (es) |
KR (1) | KR20140040774A (es) |
CN (1) | CN103608347B (es) |
AR (1) | AR086589A1 (es) |
BR (1) | BR112013030909A2 (es) |
CA (1) | CA2836202A1 (es) |
EA (1) | EA201391769A1 (es) |
ES (1) | ES2597034T3 (es) |
IL (1) | IL229513A0 (es) |
MX (1) | MX2013014082A (es) |
PL (1) | PL2716642T3 (es) |
PT (1) | PT2716642T (es) |
TW (1) | TW201311685A (es) |
WO (1) | WO2012165399A1 (es) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102012200349A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung |
EP2840076B1 (en) * | 2012-04-16 | 2017-10-25 | TOA Eiyo Ltd. | Bicyclic compound |
KR20150005936A (ko) | 2012-04-25 | 2015-01-15 | 다케다 야쿠힌 고교 가부시키가이샤 | 질소화 헤테로시클릭 화합물 |
CN103508918B (zh) * | 2012-06-18 | 2015-09-09 | 上海医药工业研究院 | 带有环丁基的α-羟基β-氨基酯类化合物及其制备方法 |
EP2873669A4 (en) | 2012-07-13 | 2015-11-25 | Takeda Pharmaceutical | HETEROCYCLIC COMPOUND |
US8796305B2 (en) * | 2012-11-05 | 2014-08-05 | Bayer Pharma Aktiengesellschaft | Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
US8778964B2 (en) * | 2012-11-05 | 2014-07-15 | Bayer Pharma Aktiengesellschaft | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use |
US9126998B2 (en) | 2012-11-05 | 2015-09-08 | Bayer Pharma AG | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
US9624214B2 (en) | 2012-11-05 | 2017-04-18 | Bayer Pharma Aktiengesellschaft | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
MX2015006856A (es) | 2012-11-30 | 2016-02-17 | Astellas Pharma Inc | Compuestos imidazopiridina. |
US9834520B2 (en) | 2013-03-14 | 2017-12-05 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2014195333A1 (de) * | 2013-06-04 | 2014-12-11 | Bayer Pharma Aktiengesellschaft | 3-aryl-substituierte imidazo[1,2-a]pyridine und ihre verwendung |
JP6427491B2 (ja) | 2013-07-03 | 2018-11-21 | 武田薬品工業株式会社 | 複素環化合物 |
ES2950424T3 (es) | 2013-07-03 | 2023-10-09 | Takeda Pharmaceuticals Co | Compuesto de amida |
PE20160201A1 (es) | 2013-07-10 | 2016-05-06 | Bayer Pharma AG | Bencil-1h-pirazol[3,4-b]piridinas y su uso |
WO2015012328A1 (ja) * | 2013-07-24 | 2015-01-29 | 武田薬品工業株式会社 | 複素環化合物 |
US20160176880A1 (en) * | 2013-08-08 | 2016-06-23 | Bayer Pharma Aktiengesellschaft | Substituted imidazo[1,2-a]pyrazinecarboxamides and use thereof |
WO2015018814A1 (de) * | 2013-08-08 | 2015-02-12 | Bayer Pharma Aktiengesellschaft | Substituierte pyrazolo[1,5-a]pyridin-3-carboxamide und ihre verwendung |
WO2015082411A1 (de) * | 2013-12-05 | 2015-06-11 | Bayer Pharma Aktiengesellschaft | Aryl- und hetaryl-substituierte imidazo[1,2-a]pyridin-3-carboxamide und ihre verwendung |
WO2015106268A1 (en) | 2014-01-13 | 2015-07-16 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
CA2939793A1 (en) * | 2014-02-19 | 2015-08-27 | Bayer Pharma Aktiengesellschaft | 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines |
US20170057954A1 (en) * | 2014-03-21 | 2017-03-02 | Bayer Pharma Aktiengesellschaft | Substituted imidazo[1,2-a]pyridinecarboxamides and their use |
WO2015140199A1 (de) * | 2014-03-21 | 2015-09-24 | Bayer Pharma Aktiengesellschaft | Cyano-substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung |
CA2947376A1 (en) * | 2014-05-02 | 2015-11-05 | Bayer Pharma Aktiengesellschaft | Imidazo[1,2-a]pyridines as stimulators of soluble guanylate cyclase for treating cardiovascular diseases |
US20170057958A1 (en) | 2014-05-02 | 2017-03-02 | Bayer Pharma Aktiengesellschaft | Enantiomers of the n-(2-amino-5-fluoro-2-methylpentyl)-8-[(2,6-difluorobenzyl)oxy]-2-methylimidazo[1,2-a]pyridine-3-carboxamide, as well as of the di- and trifluoro derivatives for the treatment of cardiovascular diseases |
WO2015165933A2 (de) * | 2014-05-02 | 2015-11-05 | Bayer Pharma Aktiengesellschaft | 6-substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung |
CA2947372A1 (en) * | 2014-05-02 | 2015-11-05 | Bayer Pharma Aktiengesellschaft | 6-chlorine-substituted imidazo[1,2-a]pyridine carboxamides and the use thereof as soluble guanylate cyclase stimulators |
CN103965193B (zh) * | 2014-05-30 | 2016-04-06 | 浙江司太立制药股份有限公司 | N-(苯氧烷基)咪唑并[1,2-a]吡啶-3-酰胺类化合物及其制备方法 |
JP2017537922A (ja) * | 2014-12-02 | 2017-12-21 | バイエル・ファルマ・アクティエンゲゼルシャフト | 置換ピラゾロ[1,5−a]ピリジンおよびイミダゾ[1,2−a]ピラジンならびにそれらの使用 |
JP2017536396A (ja) | 2014-12-02 | 2017-12-07 | バイエル・ファルマ・アクティエンゲゼルシャフト | ヘテロアリール置換イミダゾ[1,2−a]ピリジンおよびその使用 |
WO2016101118A1 (en) * | 2014-12-23 | 2016-06-30 | Merck Sharp & Dohme Corp. | Amidoethyl azole orexin receptor antagonists |
KR20180002657A (ko) | 2015-05-06 | 2018-01-08 | 바이엘 파마 악티엔게젤샤프트 | 전신 경화증 (SSc)에 수반되는 수족지 궤양 (DU)의 치료를 위한 sGC 자극제, sGC 활성화제 단독 및 PDE5 억제제와의 조합물의 용도 |
WO2016198691A1 (en) | 2015-06-11 | 2016-12-15 | Basilea Pharmaceutica Ag | Efflux-pump inhibitors and therapeutic uses thereof |
CN113750102A (zh) | 2015-07-23 | 2021-12-07 | 拜耳制药股份公司 | 可溶性鸟苷酸环化酶的刺激剂和/或活化剂及其用途 |
CA2998375A1 (en) | 2015-09-17 | 2017-03-23 | Marvin J. Miller | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection |
CN108463224A (zh) | 2015-12-14 | 2018-08-28 | 铁木医药有限公司 | sGC刺激剂用于胃肠功能障碍治疗的应用 |
WO2018069148A1 (de) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten |
WO2018069126A1 (de) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend sgc stimulatoren und mineralocorticoid-rezeptor-antagonisten |
US20190381039A1 (en) | 2016-12-13 | 2019-12-19 | Cyclerion Therapeutics, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF ESOPHAGEAL MOTILITY DISORDERS |
WO2018184976A1 (de) | 2017-04-05 | 2018-10-11 | Bayer Pharma Aktiengesellschaft | Substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung |
WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
EP3787610A1 (en) | 2018-04-30 | 2021-03-10 | Bayer Aktiengesellschaft | The use of sgc activators and sgc stimulators for the treatment of cognitive impairment |
EA202092680A1 (ru) | 2018-05-15 | 2021-04-13 | Байер Акциенгезельшафт | 1,3-тиазол-2-ил-замещенные бензамиды для лечения заболеваний, ассоциированных с сенситизацией нервных волокон |
EP3574905A1 (en) | 2018-05-30 | 2019-12-04 | Adverio Pharma GmbH | Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group |
US20210177846A1 (en) | 2018-07-11 | 2021-06-17 | Cyclerion Therapeutics, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS |
US20220128561A1 (en) | 2019-01-17 | 2022-04-28 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble gyanylyl cyclase (sgc) |
CN111518061B (zh) * | 2019-02-01 | 2023-08-25 | 鲁南制药集团股份有限公司 | 一种(e)-3-(3-呋喃基)丙烯酸的制备方法 |
WO2020164008A1 (en) | 2019-02-13 | 2020-08-20 | Bayer Aktiengesellschaft | Process for the preparation of porous microparticles |
CN110229067A (zh) * | 2019-06-05 | 2019-09-13 | 南京焕然生物科技有限公司 | 一种2-氨基茚制备方法 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07242666A (ja) | 1994-03-08 | 1995-09-19 | Fujisawa Pharmaceut Co Ltd | 複素環化合物 |
SE9700661D0 (sv) | 1997-02-25 | 1997-02-25 | Astra Ab | New compounds |
AU4543899A (en) * | 1998-06-08 | 1999-12-30 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
DE19846514A1 (de) | 1998-10-09 | 2000-04-20 | Bayer Ag | Neue Heterocyclyl-methyl-substituierte Pyrazole |
GB9824310D0 (en) | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
EP1237849A1 (en) | 1999-11-05 | 2002-09-11 | University College London | Activators of soluble guanylate cyclase |
DE10021069A1 (de) | 2000-04-28 | 2001-10-31 | Bayer Ag | Substituiertes Pyrazolderivat |
CA2311483A1 (en) | 2000-06-12 | 2001-12-12 | Gregory N Beatch | IMIDAZO [1,2-A] PYRIDINIC ETHERS AND USES THEREOF |
DE10132416A1 (de) | 2001-07-04 | 2003-01-16 | Bayer Ag | Neue Morpholin-überbrückte Pyrazolopyridinderivate |
WO2003076408A2 (en) | 2002-03-08 | 2003-09-18 | Abbott Laboratories | Indazole derivatives that are activators of soluble guanylate cyclase |
DE10216145A1 (de) | 2002-04-12 | 2003-10-23 | Bayer Ag | Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom |
DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
DE10222550A1 (de) | 2002-05-17 | 2003-11-27 | Bayer Ag | Substituierte Benzyl-pyrazolopyridine |
DE102006020327A1 (de) | 2006-04-27 | 2007-12-27 | Bayer Healthcare Ag | Heterocyclisch substituierte, anellierte Pyrazol-Derivate und ihre Verwendung |
DE102006021733A1 (de) * | 2006-05-09 | 2007-11-22 | Bayer Healthcare Ag | 3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung |
DE102006043443A1 (de) | 2006-09-15 | 2008-03-27 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
DE102006054757A1 (de) | 2006-11-21 | 2008-05-29 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
DE102008063992A1 (de) | 2008-12-19 | 2010-09-02 | Lerner, Zinoviy, Dipl.-Ing. | Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung |
DE102009004245A1 (de) | 2009-01-09 | 2010-07-15 | Bayer Schering Pharma Aktiengesellschaft | Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung |
SG10201502109VA (en) | 2010-03-18 | 2015-05-28 | Pasteur Institut Korea | Anti-infective compounds |
-
2012
- 2012-05-29 MX MX2013014082A patent/MX2013014082A/es unknown
- 2012-05-29 AR ARP120101881A patent/AR086589A1/es not_active Application Discontinuation
- 2012-05-29 WO PCT/JP2012/063695 patent/WO2012165399A1/ja active Application Filing
- 2012-05-29 EP EP12791965.2A patent/EP2716642B1/en active Active
- 2012-05-29 CN CN201280026953.4A patent/CN103608347B/zh active Active
- 2012-05-29 BR BR112013030909A patent/BR112013030909A2/pt not_active IP Right Cessation
- 2012-05-29 EA EA201391769A patent/EA201391769A1/ru unknown
- 2012-05-29 TW TW101119128A patent/TW201311685A/zh unknown
- 2012-05-29 CA CA2836202A patent/CA2836202A1/en not_active Abandoned
- 2012-05-29 PL PL12791965T patent/PL2716642T3/pl unknown
- 2012-05-29 ES ES12791965.2T patent/ES2597034T3/es active Active
- 2012-05-29 PT PT127919652T patent/PT2716642T/pt unknown
- 2012-05-29 JP JP2013518087A patent/JP5975025B2/ja not_active Expired - Fee Related
- 2012-05-29 KR KR1020137034903A patent/KR20140040774A/ko not_active Application Discontinuation
-
2013
- 2013-11-20 IL IL229513A patent/IL229513A0/en unknown
- 2013-11-26 US US14/090,074 patent/US9447090B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA2836202A1 (en) | 2012-12-06 |
TW201311685A (zh) | 2013-03-16 |
CN103608347B (zh) | 2016-04-27 |
WO2012165399A1 (ja) | 2012-12-06 |
KR20140040774A (ko) | 2014-04-03 |
EP2716642A4 (en) | 2014-12-03 |
BR112013030909A2 (pt) | 2016-12-06 |
PT2716642T (pt) | 2016-10-17 |
ES2597034T3 (es) | 2017-01-13 |
EP2716642B1 (en) | 2016-07-20 |
JPWO2012165399A1 (ja) | 2015-02-23 |
MX2013014082A (es) | 2014-03-21 |
EA201391769A1 (ru) | 2014-04-30 |
JP5975025B2 (ja) | 2016-08-23 |
CN103608347A (zh) | 2014-02-26 |
US20140088080A1 (en) | 2014-03-27 |
IL229513A0 (en) | 2014-01-30 |
EP2716642A1 (en) | 2014-04-09 |
PL2716642T3 (pl) | 2017-01-31 |
US9447090B2 (en) | 2016-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR086589A1 (es) | Compuestos imidazopiridina | |
EA202090659A1 (ru) | СОСТАВЫ, СОДЕРЖАЩИЕ 6-(2-ГИДРОКСИ-2-МЕТИЛПРОПОКСИ)-4-(6-(6-((6-МЕТОКСИПИРИДИН-3-ИЛ)МЕТИЛ)-3,6-ДИАЗАБИЦИКЛО[3.1.1]ГЕПТАН-3-ИЛ)ПИРИДИН-3-ИЛ)ПИРАЗОЛО[1,5-a]ПИРИДИН-3-КАРБОНИТРИЛ | |
AR101175A1 (es) | Imidazopiridinas e imidazopirazinas como inhibidores de lsd1 | |
AR089424A1 (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
AR086019A1 (es) | COMPUESTOS DE PIRROLO SULFONAMIDA PARA MODULACION DE LA ACTIVIDAD DEL RECEPTOR HUERFANO g RELACIONADO AL RECEPTOR NUCLEAR HUERFANO RAR (RORg, NR1F3) Y PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS Y AUTOINMUNES CRONICAS | |
JP2016523270A5 (es) | ||
AR078157A1 (es) | Derivados de pirazol-[4,5-d]pirrolo[2,3-b]piridina inhibidores de tirosinquinasas jak 2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer | |
DK3489238T3 (da) | Farmaceutiske sammensætninger af 6h-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-on- og [1,2,4]triazolo[1,5-c]pteridin-5(6h)-on-derivater som pde1-inhibitorer til behandling af for eksempel neurologiske lidelser | |
AR095341A1 (es) | Compuestos y usos para la modulación de hemoglobina | |
AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
AR088235A1 (es) | Derivados de pirazoloquinolina | |
CU20160192A7 (es) | Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble | |
AR090005A1 (es) | Imidazo[1,2-a]pirimidinas y piridinas sustituidas | |
AR090572A1 (es) | Derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos | |
AR091781A1 (es) | Antagonistas del receptor de 5-ht3 | |
AR053364A1 (es) | Compuesto de 1h-imidazo 84,5-c) piridin -2- ilo, composicion farmaceutica que lo comprende, proceso para prepararla y su uso para preparar un medicamento para tratamiento de cancer o artritis | |
AR080802A1 (es) | Compuestos de complejos de fe (iii) para el tratamiento y la profilaxis de los sintomas de deficiencia de hierro y anemias por deficiencia de hierro | |
AR085099A1 (es) | Derivados de (1,2,4)triazolo[4,3-a]quinoxalina como inhibidores de fosfodiesterasas | |
ATE486602T1 (de) | Pyrrolo (3, 2, 1-ij) chinolin-4-on-derivate zur behandlung von tuberkulose | |
PE20191323A1 (es) | PIRAZOLO[3,4-b]PIRIDINAS E IMIDAZO[1,5-b]PIRIDAZINAS COMO INHIBIDORES DE PDE1 | |
AR083904A1 (es) | Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos | |
AR065333A1 (es) | Antagonistas del receptor de dopamina 2 de rapida disociacion | |
AR091455A1 (es) | Derivados 1,3-dihidro-2h-benzimidazol-2-ona sustituidos con heterociclos como agentes antivirales para el virus sincicial respiratorio | |
AR096045A1 (es) | Composición farmacéutica y formulación para prevenir o tratar el síndrome de ojo seco | |
PT2909205T (pt) | Derivados de carbamato de hexadecahidrociclopropa(e)pirrolo(1,2- a)(1,4)diazaciclopentadecinilo substituídos com 9-metilo como inibidores da protease não estrutural 3 (ns3) para o tratamento de infeções por vírus da hepatite c |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |